Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

DIPSS-Plus (Myelofibrosis)

The DIPSS-Plus incorporates three additional independent prognostic factors (low platelet count, transfusion need, and unfavorable karyotype) into the original DIPSS model to improve risk stratification in Primary Myelofibrosis.

Evidence-based context for fast calculator use

Purpose:
DIPSS-Plus refines Primary Myelofibrosis prognosis by adding karyotype, platelet count, and transfusion status to stratify transplant candidacy.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Baseline DIPSS Risk Group, Platelets < 100 x 10⁹/L?, Red Blood Cell Transfusion Dependent?, Unfavorable Karyotype?
Reference:
Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
HomeDIPSS-Plus (Myelofibrosis)
Pin your most used calculators here by clicking the star in the dropdown.

DIPSS-Plus (Myelofibrosis)

Clinical Context & Background

The DIPSS-Plus incorporates three additional independent prognostic factors (low platelet count, transfusion need, and unfavorable karyotype) into the original DIPSS model to improve risk stratification in Primary Myelofibrosis.
Primary Source EvidenceGangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
Formula Logic
DIPSS Score + Points for Platelets <100, Transfusion, and Unfavorable Karyotype.

Reference Data

Risk GroupTotal ScoreMedian Survival
Low015.4 years
Intermediate-116.5 years
Intermediate-22 - 32.9 years
High≥ 41.3 years

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use DIPSS-Plus (Myelofibrosis) when dIPSS-Plus refines Primary Myelofibrosis prognosis by adding karyotype, platelet count, and transfusion status to stratify transplant candidacy.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Baseline DIPSS Risk Group, Platelets < 100 x 10⁹/L?, Red Blood Cell Transfusion Dependent?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should DIPSS-Plus (Myelofibrosis) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can DIPSS-Plus (Myelofibrosis) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.